Followers | 295 |
Posts | 40918 |
Boards Moderated | 11 |
Alias Born | 08/30/2001 |
Thursday, April 27, 2023 5:01:38 PM
Item 3.01. Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing.
As previously disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on October 28, 2022, on October 25, 2022, Bluejay Diagnostics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) that because the closing bid price for the Company’s common stock had been below $1.00 per share for 30 consecutive business days, the Company was not in with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”).
On April 25, 2023, Nasdaq’s Listing Qualifications Staff notified the Company that it has extended the time period for the Company to regain compliance with the Minimum Bid Requirement until October 23, 2023. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 or higher for a minimum of ten consecutive business days.
The Company intends to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. Specifically, the Company has confirmed to Nasdaq that, if necessary, it will implement a reverse stock split of its outstanding common stock (if approved by the Company’s stockholders) to attempt to regain compliance. If the Company does not regain compliance within the additional compliance period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Requirement during the 180-day additional compliance period or maintain compliance with the other Nasdaq listing requirements.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1704287/000121390023033248/ea177565-8k_bluejay.htm
PROTECT YOUR ASS-ets!!
Recent BJDX News
- Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering • GlobeNewswire Inc. • 06/28/2024 03:32:47 PM
- Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering • GlobeNewswire Inc. • 06/27/2024 12:58:01 PM
- SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients • GlobeNewswire Inc. • 06/26/2024 12:00:00 PM
- Bluejay Diagnostics Announces Reverse Stock Split • GlobeNewswire Inc. • 06/17/2024 12:00:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/17/2024 11:10:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 09:24:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 01:25:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:58:54 PM
- Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering • GlobeNewswire Inc. • 01/02/2024 10:58:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 10:21:42 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 12/29/2023 10:06:56 PM
- Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering • GlobeNewswire Inc. • 12/28/2023 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/28/2023 05:15:12 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/27/2023 07:29:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 02:14:38 PM
- Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study) • GlobeNewswire Inc. • 12/27/2023 02:00:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/21/2023 10:20:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/14/2023 09:17:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/14/2023 09:16:33 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 11/21/2023 10:27:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:05:30 PM
- Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/09/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:01:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 08:15:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 01:30:22 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM